Latest results from an ongoing first-in-human phase 1a/B study of NX5948, a selective bruton's tyrosine kinase (BTK) degrader, in patients with relapsed/refractory CLL and other b-cell malignancies
Linton, Kim Collins, G. P. Forconi, F. Shah, N. N. Dixit, K. Munir, T. Omer, Z. El-Sharkawi, D. Doorduijn, J. Alencar, A.
Linton, Kim
Collins, G. P.
Forconi, F.
Shah, N. N.
Dixit, K.
Munir, T.
Omer, Z.
El-Sharkawi, D.
Doorduijn, J.
Alencar, A.
Citations
Altmetric:
Abstract
Description
Date
2024
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Linton K, Collins GP, Forconi F, Shah NN, Dixit K, Munir T, et al. Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2024 SEP;24:S360-S1. PubMed PMID: WOS:001315579603124. English.